Efficacy of topotecan treatment on antioxidant enzymes and TBA-RS levels in submandibular glands of rabbits:: An experimental study

被引:5
作者
Muluk, NB
Kisa, Ü
Kaçmaz, M
Apan, A
Koç, C
机构
[1] Kirikkale Univ, Dept ENT, Fac Med, TR-06540 Asagi Ayranci, Ankara, Turkey
[2] Kirikkale Univ, Dept Biochem, Fac Med, TR-06540 Asagi Ayranci, Ankara, Turkey
[3] Kirikkale Univ, Anesthesiol & Reanimat Dept, Fac Med, TR-06540 Asagi Ayranci, Ankara, Turkey
关键词
D O I
10.1016/j.otohns.2004.09.012
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: The aim of this study was to investigate the effects of topotecan (Hycamtin), a topoisomerase I inhibiting anticancer agent, on antioxidant enzymes (SOD, CAT, and GSH-Px) and TBA-RS values of the submandibular glands of the rabbits. STUDY DESIGN AND SETTING: The study was conveyed in two groups (Group I, II) and control with a total of 24 rabbits. Eight rabbits in group I received intravenous (i.v.) topotecan (0.25 mg/kg once daily) for 3 days. Eight rabbits in group II received i.v. topotecan (0.5 mg/kg once daily) for 3 days. On the 15th day after administration of topotecan, submandibular glands were removed and levels of the SOD, CAT, and GSH-Px and the TBA-RS in the submandibular glands of the rabbits were examined. RESULTS: SOD, CAT, and GSH-Px values were significantly higher in high-dose topotecan group compared to control group (P < 0.05). SOD and TBA-RS values were significantly higher in high-dose topotecan group compared to low-dose topotecan group (P < 0.05). CONCLUSION: It was concluded that, to prevent the hazardous effects of oxygen free radicals due to topotecan, antioxidant enzymes SOD, CAT, and GSH-Px were increased. The higher levels of the TBA-RS values in group II showed that permanent damage was present because of high-dose topotecan administration in the submandibular glands of the rabbits.
引用
收藏
页码:136 / 140
页数:5
相关论文
共 44 条
  • [1] Aebi H., 1974, Methods in Enzymatic Analysis, V2, P674, DOI [DOI 10.1016/B978-0-12-091302-2.50032-3, 10.1016/B978-0-12-091302-2.50032-3]
  • [2] Investigation of erythrocyte membrane lipid peroxidation and antioxidant defense systems of patients with coronary artery disease (CAD) documented by angiography
    Akkus, I
    Saglam, NI
    Caglayan, O
    Vural, H
    Kalak, S
    Saglam, M
    [J]. CLINICA CHIMICA ACTA, 1996, 244 (02) : 173 - 180
  • [3] World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20): : 2191 - 2194
  • [4] Treatment of squamous cell esophageal cancer with topotecan - An Eastern Cooperative Oncology Group study (E2293)
    Asbury, RF
    Lipsitz, S
    Graham, D
    Falkson, CI
    Baez, L
    Benson, AB
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01): : 45 - 46
  • [5] CARBONNEAU MA, 1991, CLIN CHEM, V37, P1423
  • [6] Topotecan: A new topoisomerase I inhibiting antineoplastic agent
    Cersosimo, RJ
    [J]. ANNALS OF PHARMACOTHERAPY, 1998, 32 (12) : 1334 - 1343
  • [7] AN ANALYSIS OF THE PATHOLOGY OF 3003 APPENDICES
    CHANG, AR
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1981, 51 (02): : 169 - 178
  • [8] CHARCOSSET JY, 1993, B CANCER, V80, P923
  • [9] DIRECT EFFECTS OF REACTIVE OXYGEN SPECIES ON COCHLEAR OUTER HAIR CELL-SHAPE IN-VITRO
    CLERICI, WJ
    DIMARTINO, DL
    PRASAD, MR
    [J]. HEARING RESEARCH, 1995, 84 (1-2) : 30 - 40
  • [10] Potential deleterious effect of β-adrenergic stimulation during warm-blood cardioplegia in rabbit hearts
    Cook, RC
    Goddard, CM
    Ashe, KA
    Chen, K
    Lichtenstein, SV
    Walley, KR
    [J]. JOURNAL OF INVESTIGATIVE SURGERY, 2001, 14 (04) : 213 - 220